UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Eptinezumab-jjmr

American journal of health-system pharmacy, 2020-07, Vol.77 (13), p.998-998

2020

Link zum Volltext

Verfügbarkeit prüfen

EPTINEZUMAB-JJMR

Pharmacy times, 2020-06, Vol.86 (6)

2020

Link zum Volltext

Verfügbarkeit prüfen

Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults

Health psychology research, 2022-01, Vol.10 (5), p.38439-38439

2022

Link zum Volltext

Verfügbarkeit prüfen

New product intros [almonertinib, bempedoic acid (first-in-class), cetirizine hydrochloride (new formulation), calaspargase pegol-mknl, eptinezumab-jjmr, lumateperone tosylate, luspatercept (new indication), remimazolam tosylate, teprotumumab-trbw]

Drugs of today (Barcelona, Spain : 1998), 2020, Vol.56 (5), p.349

Babu, S.

2020

Link zum Volltext

Verfügbarkeit prüfen

New Drugs 2021, Part 1

Nursing (Jenkintown, Pa.), 2021-02, Vol.51 (2), p.36

Hussar, Daniel A

2021

Link zum Volltext

Verfügbarkeit prüfen

Positive headline results from the Vyepti (eptinezumab-jjmr) RELIEF study: Initiating VYEPTI™ (eptinezumab-jjmr) migraine prevention during a migraine attack demonstrated positive results in the RELIEF study

PR Newswire, 2020

2020

Link zum Volltext

Verfügbarkeit prüfen

Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

Business Wire, 2024

2024

Link zum Volltext

Verfügbarkeit prüfen

Lundbeck to Present New Clinical and Real-World VYEPTI® (eptinezumab-jjmr) Data at the 65th Annual Scientific Meeting of the American Headache Society, Reinforcing Its Use in Migraine Prevention

Business Wire, 2023

2023

Link zum Volltext

Verfügbarkeit prüfen

Lundbeck to Showcase New VYEPTI® (eptinezumab-jjmr) Data at 63rd Annual Scientific Meeting of the American Headache Society (AHS)

Business Wire, 2021

2021

Link zum Volltext

Verfügbarkeit prüfen

Lundbeck’s VYEPTI™ (eptinezumab-jjmr), Quarterly Treatment for Migraine Prevention in Adults, Now Available in U.S

Business Wire, 2020

2020

Link zum Volltext

Verfügbarkeit prüfen

FDA Approves Lundbeck’s VYEPTI™ (eptinezumab-jjmr) – The First and Only Intravenous Preventive Treatment for Migraine

Business Wire, 2020

2020

Link zum Volltext

Verfügbarkeit prüfen

Orsini Pharmaceutical Services Selected To Provide VYEPTI™ (eptinezumab-jjmr) - The First And Only Intravenous Preventive Treatment For Migraine: Orsini Pharmaceutical Services is a select dispensing pharmacy for the first FDA-approved, infused migraine preventive therapy by pharmaceutical manufacturer H. Lundbeck A/S based in Denmark

PR Newswire, 2020

2020

Link zum Volltext

Verfügbarkeit prüfen

Lundbeck to Present Data on VYEPTI® (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention

Business Wire, 2022

2022

Link zum Volltext

Verfügbarkeit prüfen

The Journal of the American Medical Association Publishes Data on Efficacy and Safety of Preventive Migraine Treatment VYEPTI® (eptinezumab-jjmr) When Administered During an Active Migraine Attack

Business Wire, 2021

2021

Link zum Volltext

Verfügbarkeit prüfen

AHS Posters for Lundbeck’s VYEPTI™ (eptinezumab-jjmr) in Migraine Prevention Evaluated Early Onset of Action and Reduction in Medication-Overuse Headache

Business Wire, 2020

2020

Link zum Volltext

Verfügbarkeit prüfen

New Data Presented at 2021 American Academy of Neurology (AAN) Annual Meeting Shows VYEPTI® (eptinezumab-jjmr) Demonstrated Earlier Time to Freedom from Headache Pain and Absence of Most Bothersome Symptoms Compared to Placebo When Initiated

Business Wire, 2021

2021

Link zum Volltext

Verfügbarkeit prüfen

VYEPTI™ (eptinezumab-jjmr) Demonstrated Significant Positive Impact in Prevention of Chronic Migraine in Adults, Pivotal Phase III Study Published in Neurology Finds

Business Wire, 2020

2020

Link zum Volltext

Verfügbarkeit prüfen

New Data Presented at 2021 American Academy of Neurology (AAN) Annual Meeting Shows VYEPTI (eptinezumab-jjmr) Demonstrated Earlier Time to Freedom from Headache Pain and Absence of Most Bothersome Symptoms Compared to Placebo When Initiated

Business Wire, 2021-04-19

2021

Link zum Volltext

Verfügbarkeit prüfen

Lundbeck to Showcase New VYEPTI (eptinezumab-jjmr) Data at 63rd Annual Scientific Meeting of the American Headache Society (AHS)

Business Wire, 2021-06-03

2021

Link zum Volltext

Verfügbarkeit prüfen

Positive headline results from the Vyepti (eptinezumab-jjmr) RELIEF study

PR newswire, 2020-08-31

2020

Link zum Volltext

Verfügbarkeit prüfen

Lundbeck to Present New Clinical and Real-World VYEPTI (eptinezumab-jjmr) Data at the 65th Annual Scientific Meeting of the American Headache Society, Reinforcing Its Use in Migraine Prevention

Business Wire, 2023-06-15

2023

Link zum Volltext

Verfügbarkeit prüfen

Lundbeck to Present Data on VYEPTI (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention

Business Wire, 2022-06-09

2022

Link zum Volltext

Verfügbarkeit prüfen

Orsini Pharmaceutical Services Selected To Provide VYEPTI(TM) (eptinezumab-jjmr) - The First And Only Intravenous Preventive Treatment For Migraine

PR newswire, 2020-04-22

2020

Link zum Volltext

Verfügbarkeit prüfen

Lundbeck's VYEPTI (eptinezumab-jjmr), Quarterly Treatment for Migraine Prevention in Adults, Now Available in U.S

Business Wire, 2020-04-06

2020

Link zum Volltext

Verfügbarkeit prüfen

FDA Approves Lundbeck's VYEPTI (eptinezumab-jjmr) - The First and Only Intravenous Preventive Treatment for Migraine

Business Wire, 2020-02-22

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 237

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(173)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(128)
Life Sciences & Biomedicine
(116)
Migraine
(62)
Plant Sciences
(38)
Biological And Medical Sciences
(31)
Fundamental And Applied Biological Sciences. Psychology
(31)
Monoclonal Antibodies
(30)
Pharmaceutical Industry
(28)
Humans
(27)
Gene Silencing
(25)
Patients
(25)
Biochemistry & Molecular Biology
(24)
Fda Approval
(22)
Transgenic Plants
(21)
Agriculture
(20)
Clinical Trials
(20)
Headaches
(20)
Gene Expression
(19)
Biotechnology & Applied Microbiology
(17)
Drug Therapy
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Eptinezumab-jjmr

EPTINEZUMAB-JJMR

Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults

New product intros [almonertinib, bempedoic acid (first-in-class), cetirizine hydrochloride (new formulation), calaspargase pegol-mknl, eptinezumab-jjmr, lumateperone tosylate, luspatercept (new indication), remimazolam tosylate, teprotumumab-trbw]

New Drugs 2021, Part 1

Positive headline results from the Vyepti (eptinezumab-jjmr) RELIEF study: Initiating VYEPTI™ (eptinezumab-jjmr) migraine prevention during a migraine attack demonstrated positive results in the RELIEF study

Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

Lundbeck to Present New Clinical and Real-World VYEPTI® (eptinezumab-jjmr) Data at the 65th Annual Scientific Meeting of the American Headache Society, Reinforcing Its Use in Migraine Prevention

Lundbeck to Showcase New VYEPTI® (eptinezumab-jjmr) Data at 63rd Annual Scientific Meeting of the American Headache Society (AHS)

Lundbeck’s VYEPTI™ (eptinezumab-jjmr), Quarterly Treatment for Migraine Prevention in Adults, Now Available in U.S

FDA Approves Lundbeck’s VYEPTI™ (eptinezumab-jjmr) – The First and Only Intravenous Preventive Treatment for Migraine

Lundbeck to Present Data on VYEPTI® (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention

The Journal of the American Medical Association Publishes Data on Efficacy and Safety of Preventive Migraine Treatment VYEPTI® (eptinezumab-jjmr) When Administered During an Active Migraine Attack

AHS Posters for Lundbeck’s VYEPTI™ (eptinezumab-jjmr) in Migraine Prevention Evaluated Early Onset of Action and Reduction in Medication-Overuse Headache

New Data Presented at 2021 American Academy of Neurology (AAN) Annual Meeting Shows VYEPTI® (eptinezumab-jjmr) Demonstrated Earlier Time to Freedom from Headache Pain and Absence of Most Bothersome Symptoms Compared to Placebo When Initiated

VYEPTI™ (eptinezumab-jjmr) Demonstrated Significant Positive Impact in Prevention of Chronic Migraine in Adults, Pivotal Phase III Study Published in Neurology Finds

New Data Presented at 2021 American Academy of Neurology (AAN) Annual Meeting Shows VYEPTI (eptinezumab-jjmr) Demonstrated Earlier Time to Freedom from Headache Pain and Absence of Most Bothersome Symptoms Compared to Placebo When Initiated

Lundbeck to Showcase New VYEPTI (eptinezumab-jjmr) Data at 63rd Annual Scientific Meeting of the American Headache Society (AHS)

Positive headline results from the Vyepti (eptinezumab-jjmr) RELIEF study

Lundbeck to Present New Clinical and Real-World VYEPTI (eptinezumab-jjmr) Data at the 65th Annual Scientific Meeting of the American Headache Society, Reinforcing Its Use in Migraine Prevention

Lundbeck to Present Data on VYEPTI (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention

Orsini Pharmaceutical Services Selected To Provide VYEPTI(TM) (eptinezumab-jjmr) - The First And Only Intravenous Preventive Treatment For Migraine

Lundbeck's VYEPTI (eptinezumab-jjmr), Quarterly Treatment for Migraine Prevention in Adults, Now Available in U.S

FDA Approves Lundbeck's VYEPTI (eptinezumab-jjmr) - The First and Only Intravenous Preventive Treatment for Migraine

Suchergebnisse filtern